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oRIGINAL ARTICLE
Introduction: Microscopic examination of histologic slides or cyto-
logic specimens of mediastinal lymph node samples obtained by 
diagnostic mediastinoscopy or endobronchial ultrasound-guided fine-
needle aspiration (EBUS-TBNA) is routinely used for the staging of 
lung cancer patients. Therefore, we explored whether the detection of 
tumor-associated mRNA in lymph node samples from patients with 
suspected lung cancer adds diagnostic accuracy to conventional his-
topathological staging.
Methods: We examined 202 lymph nodes obtained by EBUS-
TBNA or mediastinoscopy from 89 patients with lung cancer. 
Lymph node samples from patients with nonmalignant disease 
were available as controls (60 samples from 31 patients). Real-
time quantitative mRNA analysis was performed for melanoma 
antigen-A genes (MAGE-A 1–6, MAGE-A 12) using a LightCycler 
480 instrument.
Results: MAGE transcript levels in control and cancer patients dif-
fered widely, and the 95% confidence interval served to define the 
threshold between negative and positive samples. MAGE 1 to 6 tran-
scripts were detected in 35 of 122 (28.7%) lymph nodes obtained 
by EBUS-TBNA and 16 of 80 (20.0%) lymph nodes obtained by 
mediastinoscopy. MAGE 12 transcripts were detected in 10 of 122 
(8.2%) lymph nodes obtained by EBUS-TBNA and 9 of 80 (11.3%) 
lymph nodes obtained by mediastinoscopy. Although the accuracy of 
histopathological diagnosis after EBUS-TBNA and mediastinoscopy 
was 69.6% and 84.1%, respectively, it increased to 81.2% and 86.4%, 
respectively, when combined with MAGE-quantitative polymerase 
chain reaction.
Conclusions: The combination of EBUS-TBNA and MAGE-
quantitative polymerase chain reaction increases the accuracy of 
tumor cell detection to the level seen with mediastinoscopy.
Key Words: Non-small cell lung cancer (NSCLC), Lymph node 
metastasis, Melanoma antigen (MAGE), Endobronchial ultrasound-
guided fine-needle aspiration (EBUS-TBNA), Mediastinoscopy.
(J Thorac Oncol. 2012;7: 690–697)
Lung cancer is the leading cause of tumor-related deaths worldwide. The 5-year survival rate ranges from 3% to 
89% depending on the extent of tumor spread.1 Surgery 
remains the cornerstone of early stage non-small cell lung 
cancer treatment, and its indication highly depends on the 
accuracy of mediastinal staging. Patients with ipsilateral 
lymph node metastasis are treated with an multimodal 
approach including surgery, whereas patients with contral-
ateral mediastinal lymph node involvement are addressed 
by primary radiochemotherapy or chemotherapy alone as a 
first-line treatment.1,2 Therefore, adequate staging is highly 
important to define accurate treatment strategies for patients 
with non-small cell lung cancer.
At present, mediastinoscopy is most often used to rule 
out or confirm mediastinal lymph node involvement. overall 
mortality ranges from 0% to 0.08%3,4 in large series, whereas 
complications occur in up to 3% of cases, primarily described 
as massive hemorrhage after injury to the great vessels (0.4%)5 
or palsy of the left recurrent laryngeal nerve (1–2%).6 Hence, 
it is an invasive diagnostic technique and less invasive staging 
methods, such as the endobronchial ultrasound-guided fine-
needle aspiration (EBUS-TBNA), may be indicated. EBUS-
TBNA is a minimally invasive method to examine mediastinal 
and hilar lymph nodes with a reported sensitivity of 79 to 
99%.7–11 However, the negative predictive value (60–99%) 
seems to be lower than for mediastinoscopy (80–99%), and 
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therefore, a confirmation of negative EBUS-TBNA findings 
by mediastinoscopy has been recommended.12
To improve the sensitivity of the preoperative diagnostic 
procedures, especially EBUS-TBNA, we looked for molecu-
lar markers to detect disseminated tumor cells in lymph node 
samples. Recently, we established a quantitative polymerase 
chain reaction (qPCR) assay to detect transcripts of cytokera-
tin 19, a well-known marker for epithelial cancer cells. We 
showed that cytokeratin 19 is detected in 100% of EBUS-
TBNA lymph node samples, excluding its diagnostic use. This 
lack of specificity of cytokeratin 19 assays may be explained 
by contamination of the samples with epithelial cells from 
the bronchial tubes.13 other highly sensitive markers such as 
ks1/4 (EpCam, CD326) or lunx (also known as palate, lung, 
and nasal epithelium carcinoma-associated gene, PLUNC) 
are also expressed in normal bronchial epithelium and there-
fore might be unsuitable for EBUS-TBNA.14 However, a highly 
specific class of markers to detect disseminated tumor cells are 
the melanoma antigens (MAGE). The MAGE proteins belong 
to the large family of human tumor-associated antigens rec-
ognized by T cells and are known to be expressed in a large 
variety of neoplasms but not in normal tissues with the notable 
exception of testis.15,16 Because of this they are also known as 
cancer-testis antigens.17 Recently, we could show that MAGE 
transcripts detected in bone marrow, blood, and lymph nodes 
are a suitable marker for the detection of disseminated tumor 
cells.18–20 In primary lung cancers, MAGE expression has been 
reported to range between 30% and 85%.19,21–25 To capture the 
various MAGE transcripts with high probability, we decided 
to use primers that amplify MAGE 1 through MAGE 6, 
which are highly homologous.26 In addition, to detect MAGE 
12 mRNA, which is frequently expressed in lung cancer,18,19 
but poorly amplified by the universal primers, we added 
MAGE 12-specific primers.
Using this molecular biological approach, we inves-
tigated the presence of disseminated tumor cells in EBUS-
TBNA samples and mediastinoscopic biopsies for a refinement 
of the staging procedure.
PATIENTS AND METHODS
Patients and Sample Preparation
The study population consisted of 120 patients, which 
were screened and prospectively included in the trial. Eighty-
nine patients had a primary lung cancer (clinical stages 
IIA–IIIB) and 31 patients presented with nonmalignant dis-
eases (sarcoidosis, tuberculosis, anthracosilicosis, or reactive 
lymphadenopathy). Study population’s age ranged from 33 
to 88 years. All patients were treated in the Department of 
Thoracic Surgery at the University Medical Center Freiburg 
between December 2007 and May 2009 after giving informed 
consent. The study was approved by the Ethical Committee 
of the University Freiburg (ethics vote 168/04). Consecutive 
patients routinely underwent staging with high-resolution spi-
ral computed tomography-scan and bronchoscopy followed 
by EBUS-TBNA and/or mediastinoscopy. For EBUS-TBNA, 
we used an olympus ViziShot system (olympus Ltd, Tokyo, 
Japan) equipped with an ultrasonic 7.5-mHz longitudinal 
transducer. A 21-gauge needle was used for 3 to 5 needle 
passes for each lymph node, as described by Herth et al.9 
Needles were cleaned between different lymph nodes accord-
ing to a specific cleaning procedure as given by the manu-
facturer and then reused. The specimen was judged visually 
by the surgeon and then analyzed directly using liquid cytol-
ogy and microscopy. In case of negative lymph node samples, 
patients were primarily subjected to thoracotomy including 
lymph node extirpation. Pathological assessment of surgically 
removed lymph nodes was used as a benchmark. The samples 
were taken from mediastinal lymph node stations 4R, 4L, and 
7 by EBUS-TBNA and 2R, 2L, 4R, 4L, and 7 by diagnostic 
mediastinoscopy. The detection of tumor cells in ipsilateral 
lymph nodes classified the patients as pN2 stage, whereas 
detection in contralateral lymph nodes classified the patients 
as pN3 stage. The sixth edition of the tumor, node, metastasis 
classification was used.27
RNA Preparation and cDNA Synthesis
Before isolation, mediastinoscopy samples were fro-
zen in RNA later (QIAGEN, Hilden, Germany) at –20C 
and before use were ground with a mortar before transfer-
ring them to RLT buffer (QIAGEN). EBUS-TBNA samples 
were directly collected in RLT buffer with -mercaptoethanol 
and stored at –80C. Subsequently, total RNA was extracted 
from the homogenate according to the manufacturer’s pro-
tocol (RNeasy mini kit, QIAGEN). RNA concentration was 
measured using a spectral photometer. cDNA was prepared 
in 20 l of reactions using 500 ng of total RNA. All reagents 
were obtained from a commercially available cDNA synthesis 
kit (1st strand cDNA synthesis for RT-PCR [AMV], Roche 
Diagnostics, Mannheim, Germany). The outcome was tested 
with a control—PCR for the -actin gene. only positive sam-
ples were further analyzed.
Cell Lines
The human colon cancer cell line HT29 has abundant 
expression of MAGE-A transcripts and was used as a posi-
tive control for the qPCR assay. The cell line was maintained 
in Dulbecco’s modified Eagle’s medium (Sigma Aldrich, 
St. Louis, Mo) supplemented with 10% fetal bovine serum 
(Sigma) and 1% penicillin/streptomycin at 37C in a humidi-
fied atmosphere containing 5% Co
2
. The cells were harvested 
when they became subconfluent.
Quantitative PCR
For the first round of PCR (preamplification), we used 
100 l of reactions containing 1 l of random-primed cDNA, 10 
l of 103 PCR buffer (200 mM Tris [pH 8.4], 500 mM KCl), 2 
l of 10 mM dNTP, 3 l of 50 mM MgCl
2
, 5 l of 5 M each 
of the outer primer, and 0.6 U TaqDNA polymerase (Invitrogen, 
Darmstadt, Germany). The cycling parameters were as follows: 
initial denaturation at 95C for 5 minutes, followed by 15 cycles 
(20 cycles for MAGE 12) of 95C for 30 seconds, 60C for 45 sec-
onds, and 72C for 45 seconds. The final extension incubation was 
performed at 72C for 10 minutes. After the first PCR, qPCR was 
performed in a LightCycler 480 instrument (Roche Diagnostics). 
Each 20 l of qPCR contained 2 l of the first reaction, 2 l 
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of 5 M each of the inner primer and 14 fl of SYBR Green 
I master (Roche Diagnostics) containing SYBR green, dNTPs, 
MgCl
2,
 and reaction buffer as described in the manufacturer’s 
data sheet. Cycling parameters were 5 minutes at 95C for initial 
activation of the enzyme, 15 seconds at 95C for denaturation, 
10 seconds at 61C for annealing, and 20 seconds at 72C for 
elongation for 40 cycles. After completion of the reaction, the 
PCR products were subjected to a melting curve analysis span-
ning the temperature range from 65 to 95C with a ramping rate 
of 0.1C/sec. The specificity of the amplification was further 
confirmed by electrophoresis on 2% ethidium bromide-stained 
agarose gels.
The combination of primers MMRP3 and MMRP4 
was used for the gene expression of all MAGE 1 to 6 genes 
together, as described by Park et al.26 For MAGE 12 a spe-
cific primer was used, because of its relatively high expression 
in lung cancer.18 The sequences of all oligonucleotide prim-
ers are listed in Supplementary Table 1. For the quantitative 
analysis of the reference housekeeping gene porphobilinogen 
desaminase (PBGD), specific primers were not added to the 
MAGE preamplification but only for the qPCR, that is., PBGD 
was measured in an effective dilution of 1:10 of the initial 
cDNA. The samples were each measured in triplicate, a nega-
tive control was also included for each sample, and an internal 
standard curve was measured in each run.
Calculations and Statistical Analysis
The quantification of gene expression was based on the 
cycle number at which the fluorescence of a sample rises above 
the background fluorescence (crossing point) and was calcu-
lated by a standardized algorithm of the software. Relative 
quantification of MAGE expression was calculated in rela-
tion to the concentration of the reference housekeeping gene 
PBGD. To determine PCR efficiency at different target RNA 
concentrations, standard curves using serial dilutions of HT29 
cDNA (1:1, 1:10, 1:100, 1:200, 1:1000) were performed for 
each experiment. In addition, for normalization, an internal 
calibrator was included in each run. Investigators performing 
qPCR were blinded concerning the histopathological results. 
All statistical analyses were performed using SPSS software 
version 17.0 for Windows (SPSS Inc., Chicago, IL). The val-
ues of p below 0.05 were considered statistically significant.
RESULTS
Figure 1 depicts the study design and how we evaluated 
the diagnostic procedures. We focused on the reported nega-
tive predictive value of EBUS-TBNA and therefore controlled 
each negative result after a diagnostic algorithm. In summary, 
the negative findings in EBUS-TBNA and mediastinoscopy 
were then assessed by open surgery, which is considered the 
gold standard.
We first analyzed the expression of MAGE transcripts 
in 60 lymph node samples from 31 patients with various non-
malignant disease conditions, as several studies had reported 
the expression of MAGE genes in chronic nonmalignant 
disease.28–31 Forty samples obtained by EBUS-TBNA and 
20 lymph node samples obtained by mediastinoscopy were 
analyzed by qPCR. Fifty-six samples (93.3%) showed no 
specific expression of mRNA transcripts for MAGE 1 to 6, 
and 54 samples (90.0%) were free of MAGE 12 transcripts. 
Four samples showed low levels of MAGE 1 to 6 transcripts 
(relative quantification values 0.0008, 0.011, 0.060, and 
0.07; two samples were from patients with sarcoidosis, one 
with anthracosilicosis, and one with reactive lymphadenopa-
thy) and six samples showed MAGE 12 expression (relative 
quantification values 0.055, 0.061, 0.100, 0.130, 0.211, and 
0.616; four samples were from patients with sarcoidosis, one 
with tuberculosis, and one with reactive lymphadenopathy). 
There was no overlap between samples, which were positive 
for MAGE 1 to 6 and MAGE 12. Given this low expression in 
control samples, we decided to define a cutoff level for the 
qPCR result. For this, we used a relative quantification value 
that we calculated from the 95% confidence interval of posi-
tive values in the control group. We obtained a threshold value 
of 0.091 for the MAGE 1 to 6 primers and 0.420 for the MAGE 
12 primers, above which MAGE expression was considered to 
be cancer specific (Table 1).
Next, we assessed the expression of MAGE tran-
scripts in 202 lymph nodes of 89 patients with lung cancer 
(for clinical characteristics of the patients see Table 2). one 
hundred twenty-two lymph node samples from 69 patients 
were obtained by EBUS-TBNA and 80 lymph nodes from 
44 patients were collected by mediastinoscopy before opera-
tion. We detected MAGE 1 to 6 mRNA in 35 of 122 (28.7%; 
median, 1.36; range, 0.100–30.4) and MAGE 12 mRNA in 10 
of 122 EBUS-TBNA samples (8.2%; median, 4.55; range, 
0.60–24.5). In the lymph node samples obtained by medi-
astinoscopy, MAGE 1 to 6 mRNA was detected in 16 of 80 
(20.0%; median, 3.24; range, 0.100–2878) and MAGE 12 
mRNA in 9 of 80 (11.3%; median, 3.00; range, 0.570–25.2) 
lymph nodes. A correlation with clinicopathological param-
eters revealed a significant correlation of MAGE 1 to 6 or 
MAGE 12 transcripts in EBUS-TBNA and mediastinoscopic 
FIGURE 1. Study design. The flow chart describes the diag-
nostic procedures used for a mediastinal lymph node analysis 
of lung cancer patients. To prevent false-negative results, 
patients with negative endobronchial ultrasound-guided 
fine-needle aspiration were subjected to mediastinoscopy, 
and patients with negative mediastinoscopy were treated by 
surgical resection.
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TABLE 1. Expression of MAGE 1–6 and MAGE 12 in Lymph Node Samples
  MAGE 1–6 Expression MAGE 12 Expression
n
Before 
Correctiona
After 
Correctionb
Before 
Correctiona
After 
Correctionb
Lymph nodes of  
control patients
 EBUS-TBNA 40 3 (7.5%) 0 2 (5.0%) 0
  Medianc  0.06  0.80  
  Rangec  0.011–0.07  0.061–0.10  
 Mediastinoscopy 20 1 (5.0%) 0 4 (20.0%) 1 (5.0%)
  Medianc  0.00008  0.17 0.62
  Rangec    0.055–0.62  
Lymph nodes of  
cancer patients
 EBUS-TBNA 122 50 (41.0%) 35 (28.7%) 29 (23.8%) 9 (7.4%)
  Medianc  0.69 1.36 0.20 4.55
  Rangec  0.0021–30.4 0.10–30.4 10–10–24.5 0.60–24.5
 Mediastinoscopy 80 31 (38.8%) 16 (20.0%) 42 (52.5%) 9 (11.3%)
  Medianc  0.10 3.24 0.058 3.00
  Rangec  0.0043–2878 0.10–2878 0.00007–25.2 0.57–25.2
a All samples with detected transcripts were regarded as positive, independent of the relative quantification value.
b only samples with a relative quantification value above the defined cutoff level (defined by the 95% confidence interval of 
positive samples in the control group) of 0.091 for MAGE 1–6 and 0.420 for MAGE 12 were regarded as positive.
c Median and range of qPCR values of positive samples are listed; if only one positive sample was detected, the relative quantification 
value of this sample is provided.
TABLE 2. Clinical Characteristics of Lung Cancer Patients and MAGE Expression
EBUS-TBNA Patients  
(n = 69)a
Mediastinoscopy Patients  
(n = 44)a
n
MAGE 
Expression pb n
MAGE 
Expression pb
Age (yr)
  60 19 4 (21.1%) 0.576 12 6 (50.03%) 0.279
 61–70 23 8 (34.8%) 29 5 (17.2%)
 >70 27 9 (33.3%) 3 3 (100.0%)
Histology
 Squamous cell carcinoma 24 7 (29.2%) 0.995 12 3 (25.0%) 0.577
 Adenocarcinoma 29 9 (31.0%) 20 6 (30.0%)
 Large cell carcinoma 7 2 (28.6%) 3 2 (66.6%)
 Small cell lung cancer 9 3 (33.3%) 9 3 (33.3%)
Tumour sizec
 pT1 8 1 (12.5%) 0.438 4 0 0.531
 pT2 36 10 (27.8%) 30 10 (33.3%)
 pT3 9 3 (33.3%) 5 2 (40.0%)
 pT4 16 7 (43.8%) 5 2 (40.0%)
Lymph node statusc
 pN0 15 0 0.004 11 0 0.033
 pN1 6 0 5 1 (20.0%)
 pN2 29 13 (44.8%) 19 8 (42.1%)
 pN3 19 8 (42.1%) 9 5 (55.6%)
a From 24 patients both EBUS-TBNA and mediastinoscopy samples were taken, resulting in a total number of 89 lung cancer 
patients.
b Two-sided p values were calculated by Pearson’s  2 test to determine a correlation between clinicopathologic parameters and 
MAGE expression. Significant p values are in bold.
c Pathologic stages were classified according to the international union against cancer (UICC) TNM-classification.20
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samples with the lymph node status (p = 0.004 and 0.033, 
respectively), whereas age, histology, and tumor size did not 
show any significant correlation (Table 2). Furthermore, we 
observed a highly significant positive correlation between high 
transcript levels of MAGE 1 to 6 and MAGE 12 levels (Figures 
2A, B; Spearman’s [rho] r = 0.422, p < 0.001 for EBUS-TBNA 
and r = 0.257, p = 0.004 for mediastinoscopy samples).
Detection of tumor-specific MAGE expression cor-
related with the finding of malignant cells in histopathology 
for mediastinoscopy samples (p = 0.010 for MAGE 1 to 6 
expression and p = 0.044 for MAGE 12 expression, Figure 3A 
and Table 3) and EBUS-TBNA samples (p < 0.001 for MAGE 
1 to 6 expression and p = 0.048 for MAGE 12 expression, 
Figure 3B and Table 3).
The extent of regional lymph node metastasis at diagnosis is 
important for therapy selection of lung cancer patients. Therefore, 
we tested whether the combination of MAGE qPCR and histopa-
thology more accurately stratifies lung cancer patients than histo-
pathology alone. In total, we included 69 patients who underwent 
preoperative EBUS-TBNA and 44 patients from whom lymph 
nodes were obtained by mediastinoscopy. MAGE 1 to 6 mRNA 
was detected in 21 of 69 patients (30.4%) and 11 of 44 patients 
FIGURE 2. Comparison between quantitative melanoma antigens 1–6 and melanoma antigens 12 expression. The relative 
quantification values of melanoma antigens 1–6 and 12 gene expression were plotted against each other on a logarithmic scale 
for endobronchial ultrasound-guided fine-needle aspiration samples (A, Spearman’s [rho] correlation coefficient, r = 0.422; p < 
0.001) and mediastinoscopy samples (B, Spearman’s [rho] correlation coefficient r = 0.257; p = 0.004).
FIGURE 3. Mediastinal lymph node metas-
tasis of a squamous carcinoma of the lung. 
A, Histological specimen showing compact 
formations of tumor cells () within a 
desmoplastic stroma containing few rests of 
lymphatic tissue (L). Hematoxylin and eosin 
(HE)staining, 100-fold magnification. B, 
Cell cluster of an endobronchial ultrasound-
guided fine-needle aspiration specimen with 
a group of tumor cells adjacent to residual 
lymphocytes of the lymph node. Note intra-
cellular keratinization in one of the tumor 
cells (). HE staining of the liquid-based 
cytology, 200-fold magnification.
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(25.0%), respectively. Cancer-specific MAGE 12 transcripts 
were detected in 8 of 69 (11.6%) and 7 of 44 (15.9%) patients. 
For EBUS-TBNA samples, all eight MAGE 12-positive patients 
also showed MAGE 1 to 6 transcripts, whereas three of seven 
MAGE 12-positive patients who underwent mediastinoscopy 
showed no MAGE 1 to 6 transcripts. All but one of the patients, 
who displayed cancer-specific MAGE transcript levels before 
operation, were postoperatively diagnosed with extensive 
regional lymph node metastasis (pN2–3). Given these obser-
vations, we combined MAGE qPCR with histopathology of 
the EBUS-TBNA and mediastinoscopy samples. We reasoned 
that a more sensitive preoperative diagnostic procedure might 
prevent nonrecommended operation of patients with extended 
lymph node spread (pN2 or pN3 disease). Among our patients, 
cytopathological evaluation of preoperative EBUS-TBNA alone 
correctly identified 27 of 48 patients as pN2 or pN3 (accuracy 
69.6%) and histopathological evaluation of mediastinoscopy 
21 of 28 patients (accuracy 84.1%), respectively. The addition 
of cancer-specific MAGE expression resulted in increased sen-
sitivity in tumor cell detection, providing a correct diagnosis 
of pN2 or pN3 in 35 of 48 EBUS-TBNA samples (accuracy 
81.2%; Table 4) and 23 of 28 mediastinoscopy samples (accu-
racy 86.4%; Table 4).
DISCUSSION
In this study, we investigated the impact of qPCR on the 
detection of disseminated tumor cell mRNA in mediastinal 
lymph node samples and on its accuracy when combined with 
conventional histopathology. We established a highly sensitive 
and tumor-specific real-time PCR for the quantitative assess-
ment of disseminated tumor cells in lymph node samples of 
lung cancer patients.
Among our control patients, we detected MAGE 12 
transcripts in four lymph nodes from patients with sarcoi-
dosis. Although MAGE expression has not been linked 
to sarcoidosis until to date, these results are in agreement 
with previous studies, which detected expression of MAGE 
mRNA in patients with chronic lung damage.28,31 In our 
study, the relative expression of MAGE transcripts in sam-
ples from patients with a nonmalignant bronchial disease 
was low, and cutoff levels for cancer-specific MAGE 1 to 6 
and MAGE 12 expression could be defined. By these cut-
off levels based on the 95% confidence interval of control 
samples, we were able to clearly separate MAGE expression 
values from control and cancer patients. By this, our assay 
was designed for high specificity to exclude false-positive 
samples, while on the other hand resulting in a decrease of 
sensitivity. Therefore, we consider our MAGE qPCR assay 
to be additive to cytological/histological analysis of samples 
investigated by EBUS-TBNA or mediastinoscopy.
In patients with primary lung cancer, we detected 
MAGE 1 to 6 expression in 28.7% of EBUS-TBNA and 
20.0% of mediastinoscopy samples, and MAGE 12 expres-
sion in 8.2% of EBUS-TBNA and 11.3% of mediastinoscopy 
samples (Table 4). We could not find any correlation between 
MAGE gene expression and the histological tumor type, con-
firming the results of several previous studies.19,23–25 The rather 
low detection rate of MAGE 12 may be related to the intratu-
moral heterogeneity of MAGE expression, which has also been 
reported for melanoma.32,33 Differences in promoter methyla-
tion, which regulate MAGE expression on a transcriptional 
level in different cellular subtypes,34,35 were suggested as an 
underlying mechanism. For example, a recent study described 
MAGE transcript up-regulation by genomic hypomethylation 
after incubation of normal tissue with cigarette smoke concen-
trate for up to 9 months.30 This finding supports the view that 
MAGE gene expression is linked to early events in carcinogen-
esis, especially in its role to inhibit the pro-apoptotic functions 
of wild-type p53.36–38
Furthermore, we tested whether MAGE qPCR could 
increase the diagnostic accuracy of the currently used meth-
ods EBUS-TBNA and mediastinoscopy. In our hands, routine 
cytology of EBUS-TBNA samples was less sensitive for the 
TABLE 3. Correlation of MAGE 1–6 and MAGE 12  
Expression with Histopathologic Tumor Diagnosis
Histopathologic 
Tumor Diagnosis No. of 
Lymph Node 
Samples (%) paNegative Positive
EBUS-TBNA  
(n = 122)
 MAGE 1–6
  Negative 55 32 87 (71.3) <0.001
  Positive 6 29 35 (28.7)
 MAGE 12
  Negative 59 53 112 (91.8) 0.048
  Positive 2 8 10 (8.2)
Mediastinoscopy 
(n = 80)
 MAGE 1–6
  Negative 39 25 64 (80.0) 0.010
  Positive 4 12 16 (20.0)
 MAGE 12
  Negative 41 30 71 (88.8) 0.044
  Positive 2 7 9 (11.3)b
a Determined by 2 test.
b Percentages add up to more than 100.0 because of rounding for one decimal.
TABLE 4. Statistical Measures for the Applied Preoperative Diagnostic Assays for Lymph Node Staging
EBUS-TBNA Mediastinoscopy
Sensitivity (%) Specificity (%) Accuracy (%) Sensitivity (%) Specificity (%) Accuracy (%)
Histopathology only 56.3 100.0 69.6 75.0 100.0 84.1
MAGE qPCR only 43.8 100.0 60.9 46.4 93.8 63.6
Combined assay 72.1 100.0 81.2 82.1 93.8 86.4
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detection of lymph node involvement in lung cancer patients 
than histopathology of mediastinoscopy samples (accuracy 
69.6% and 84.1%, respectively). The addition of the quan-
titative MAGE qPCR assay to cytologic diagnosis improved 
the accuracy to 81.2% and 86.4%, respectively. The increase 
was more pronounced for EBUS-TBNA, resulting in a com-
parable accuracy as for mediastinoscopy alone. The sensi-
tivity of EBUS-TBNA in our study is 56.3% and therefore 
lower compared with published literature (79–95%).7 This 
is probably due to the relatively low number of patients and 
the recent establishment of EBUS-TBNA as a diagnostic 
procedure in our department at the time of the study. EBUS-
TBNA is a challenging procedure that requires consider-
able expertise and training, and the reported false-negative 
rate in most published studies indicates that EBUS-TBNA 
is largely operator dependent.7 However, because we show 
that a quantitative MAGE qPCR assay supplements EBUS-
TBNA in the diagnostic setting and ensures high diagnos-
tic accuracy of EBUS-TBNA from the beginning, it could 
provide significant advantages during the necessary training 
periods of clinicians.39,40
Several studies indicate that detection of few dissemi-
nated cancer cells in a pN0 staged lymph node has an impact 
on survival.41,42 Whether MAGE positive lymph nodes predict 
poor survival has not been analyzed so far and demands larger 
diagnostic studies. Taken together, molecular-pathological 
detection of MAGE transcripts in lymph nodes may be used in 
mediastinal staging, especially as addition to the less invasive 
EBUS-TBNA. As mediastinoscopy is an invasive method, 
we suggest future prospective studies on larger cohorts of 
patients to investigate whether EBUS-TBNA in combination 
with MAGE qPCR could replace mediastinoscopy for routine 
staging of lung cancer and therapy planning.
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